EndoQuest submits IDE application for PARADIGM clinical study
EndoQuest Robotics submitted an IDE application to FDA for the PARADIGM study of its endoluminal robotic platform.
Evidence notes
- The IDE submission covered a prospective clinical study for robotic colorectal procedures using EndoQuest's flexible platform.
- The event precedes FDA IDE grant and first-human-study execution.
Company context
EndoQuest Robotics develops a flexible endoluminal surgical robot for procedures performed through the body’s natural orifices. Founded in Houston as ColubrisMX and rebranded in 2022, the company combines steerable endoscopy with robotic instrument control for upper and lower gastrointestinal interventions. Its investigational ELS System is intended to enable precise, scar-free surgery without external incisions.